Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
Quick Look: An MHLW panel recommended approval for two NMEs on April 27: Boehringer’s nerandomilast and Moderna’s mRNA COVID-19 vaccine. The session also backed label expansions for Sotyktu, Fasenra, and Alecensa, while the ministry reported plans to broaden indications for…
To read the full story
Related Article
- Japan Approves Jascayd, mNEXSPIKE, Zepbound OSA Use, Others
May 19, 2026
- Japan Panel to Review Boehringer’s IPF Drug, Moderna COVID Shot on April 27
April 21, 2026
- MHLW Council Clears Public Knowledge Filing for MabCampath in T-PLL
October 1, 2025
- Chugai Files Alecensa for ALK-Positive Solid Tumors in Japan
June 27, 2025
- GSK’s RSV Vaccine Arexvy Filed for High-Risk Adults Aged 18-49 in Japan
June 23, 2025
- Moderna Files Next-Gen COVID Vaccine in Japan
June 23, 2025
- Boehringer Files Nerandomilast for Pulmonary Fibrosis in Japan
June 13, 2025
- BMS Files Label Expansion of Sotyktu for Psoriatic Arthritis in Japan
June 9, 2025
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…